Synopsis: A Rs. 500 crore qualified institutional placement has closed with participation from the Abu Dhabi Investment Authority, Goldman Sachs, and several ValueQuest funds, adding fresh institutional capital to a specialty fats manufacturer that has been growing revenue at a rapid clip while leaning increasingly on debt and working capital to fund that growth.
Shares of a specialty fats and butter manufacturer came into focus after the company’s board approved allotment of 34,01,360 equity shares to institutional buyers, closing a qualified institutional placement that opened on June 29 and concluded on July 2, 2026.
With a market capitalisation of Rs. 9,492.46 crore, the shares of Manorama Industries Limited were trading at Rs. 1,589.80 per share, up 0.54 percent from its previous closing price of Rs. 1,581.20 apiece. The stock trades at a P/E of roughly 41.98 times trailing earnings.
The issue was priced at Rs. 1,470 per share, a discount of Rs. 77.18, or 4.99 percent, to the floor price of Rs. 1,547.18, raising the full Rs. 500 crore the company had targeted. Following allotment, paid-up equity capital rose from Rs. 11.94 crore to Rs. 12.62 crore, with the total share count increasing from 5,97,08,530 to 6,31,09,890 shares, a dilution of roughly 5.7 percent for existing shareholders. That dilution is the direct, mechanical cost of the raise: per-share metrics such as EPS and book value will be spread across a larger base going forward, even though the capital itself strengthens the balance sheet.
The list of allottees is notable for its quality. Three ValueQuest-managed funds together picked up 50 percent of the issue, the Abu Dhabi Investment Authority took 6.44 percent, and the remainder went to a mix of global names including Goldman Sachs, Morgan Stanley, Citigroup, and several WhiteOak Capital mutual fund schemes. This kind of participation from sovereign wealth and marquee global institutional investors is generally read as a vote of confidence in the growth story, though retail investors should note that QIP allottees typically operate with different time horizons and cost bases than retail shareholders buying at current market prices.
Why the Company Needed the Capital
Manorama’s growth over the past two years has been genuinely rapid: trailing twelve-month sales stand at Rs. 1,208 crore against Rs. 771 crore for FY25 and Rs. 457 crore for FY24, while profit has compounded at 162 percent on a trailing basis and 37 percent annually over five years. But that growth has come with a rising debt load and a persistently negative operating cash flow that the QIP appears designed to address.
Borrowings jumped from Rs. 110 crore in FY23 to Rs. 346 crore in FY24 and Rs. 482 crore in FY25, before easing slightly to Rs. 376 crore by September 2025. Operating cash flow was negative Rs. 154 crore in FY24 and negative Rs. 59 crore in FY25, despite the company reporting healthy accounting profits in both years.
The gap traces back to the nature of Manorama’s raw material sourcing. The company procures tree-borne seeds, sal, mango, shea, and similar exotic seeds, on a seasonal harvest cycle, which forces it to build large inventory positions ahead of demand. Inventory days have run as high as 586 in FY24 and 516 in FY25, pushing the overall cash conversion cycle to 551 days, extraordinarily long by conventional manufacturing standards, though largely explained by the seasonal, agriculture-linked nature of the business rather than any operational mismanagement. Debtor days have also crept up, from 36.8 to 48.2 in the most recent data, a smaller but still relevant working capital drag.
Separately, the company has been expanding internationally, having set up eight new subsidiaries across West Africa, the UAE, and Brazil in FY25, and more recently approved roughly Rs. 350 crore of support for a factory being set up by its Burkina Faso subsidiary. Fresh equity capital gives the company room to fund this expansion and manage its working capital cycle without leaning entirely on borrowed money, a reasonably conservative approach given how much debt had already built up. CARE Ratings upgraded the company’s long-term facility rating to A+ in late March 2026, a signal that credit quality has been improving even before this raise, and the fresh capital should support that trajectory further.
For retail investors, the trade-off here is fairly clear: near-term dilution and continued rich valuation, the stock trades at roughly 15 times book value against peers in the food products space typically valued far lower, against a business that has shown real, sustained growth and has now brought in credible long-term institutional capital rather than more debt to fund its next phase of expansion.
Business Overview
Incorporated in 2005 and headquartered in Raipur, Chhattisgarh, Manorama Industries manufactures cocoa butter equivalents and specialty fats from sal, mango, shea, and other tree-borne seeds under a “waste to wealth” model, serving the chocolate, confectionery, bakery, and cosmetics industries globally, including markets in Japan, Italy, Germany, and the UK. For the trailing twelve months, the company reported revenue of Rs. 1,208 crore and net profit of Rs. 216 crore, up from Rs. 771 crore and Rs. 112 crore respectively in FY25.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
